These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

408 related items for PubMed ID: 7636216

  • 1. An anti-murine CD3 monoclonal antibody with a low affinity for Fc gamma receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity.
    Alegre ML, Tso JY, Sattar HA, Smith J, Desalle F, Cole M, Bluestone JA.
    J Immunol; 1995 Aug 01; 155(3):1544-55. PubMed ID: 7636216
    [Abstract] [Full Text] [Related]

  • 2. Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells.
    Cole MS, Anasetti C, Tso JY.
    J Immunol; 1997 Oct 01; 159(7):3613-21. PubMed ID: 9317161
    [Abstract] [Full Text] [Related]

  • 3. A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo.
    Alegre ML, Peterson LJ, Xu D, Sattar HA, Jeyarajah DR, Kowalkowski K, Thistlethwaite JR, Zivin RA, Jolliffe L, Bluestone JA.
    Transplantation; 1994 Jun 15; 57(11):1537-43. PubMed ID: 8009586
    [Abstract] [Full Text] [Related]

  • 4. Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody.
    Alegre ML, Collins AM, Pulito VL, Brosius RA, Olson WC, Zivin RA, Knowles R, Thistlethwaite JR, Jolliffe LK, Bluestone JA.
    J Immunol; 1992 Jun 01; 148(11):3461-8. PubMed ID: 1534096
    [Abstract] [Full Text] [Related]

  • 5. Comparison of in vivo efficacy and mechanism of action of antimurine monoclonal antibodies directed against TCR alpha beta (H57-597) and CD3 (145-2C11).
    Henrickson M, Reid J, Bellet JS, Sawchuk SS, Hirsch R.
    Transplantation; 1995 Oct 27; 60(8):828-35. PubMed ID: 7482743
    [Abstract] [Full Text] [Related]

  • 6. Fc receptor binding of anti-CD3 monoclonal antibodies is not essential for immunosuppression, but triggers cytokine-related side effects.
    Vossen AC, Tibbe GJ, Kroos MJ, van de Winkel JG, Benner R, Savelkoul HF.
    Eur J Immunol; 1995 Jun 27; 25(6):1492-6. PubMed ID: 7614975
    [Abstract] [Full Text] [Related]

  • 7. Modulation of antigen-specific T cell response by a non-mitogenic anti-CD3 antibody.
    Li J, Davis J, Bracht M, Carton J, Armstrong J, Gao W, Scallon B, Fung R, Emmell E, Zimmerman M, Griswold DE, Li L.
    Int Immunopharmacol; 2006 Jun 27; 6(6):880-91. PubMed ID: 16644473
    [Abstract] [Full Text] [Related]

  • 8. Contrasting in vivo effects on T helper cell functions induced by mitogenic (intact) versus nonmitogenic (F(ab')2) anti-CD3 monoclonal antibody.
    Sawchuk SS, Gates R, Hirsch R.
    Transplantation; 1995 Dec 15; 60(11):1331-7. PubMed ID: 8525530
    [Abstract] [Full Text] [Related]

  • 9. Engineering a humanized bispecific F(ab')2 fragment for improved binding to T cells.
    Rodrigues ML, Shalaby MR, Werther W, Presta L, Carter P.
    Int J Cancer Suppl; 1992 Dec 15; 7():45-50. PubMed ID: 1428403
    [Abstract] [Full Text] [Related]

  • 10. In vitro characterization of five humanized OKT3 effector function variant antibodies.
    Xu D, Alegre ML, Varga SS, Rothermel AL, Collins AM, Pulito VL, Hanna LS, Dolan KP, Parren PW, Bluestone JA, Jolliffe LK, Zivin RA.
    Cell Immunol; 2000 Feb 25; 200(1):16-26. PubMed ID: 10716879
    [Abstract] [Full Text] [Related]

  • 11. Immunosuppressive properties of anti-CD3 single-chain Fv and diabody.
    Le Gall F, Reusch U, Moldenhauer G, Little M, Kipriyanov SM.
    J Immunol Methods; 2004 Feb 01; 285(1):111-27. PubMed ID: 14871540
    [Abstract] [Full Text] [Related]

  • 12. Quantitative in vivo comparisons of the Fc gamma receptor-dependent agonist activities of different fucosylation variants of an immunoglobulin G antibody.
    Scallon B, McCarthy S, Radewonuk J, Cai A, Naso M, Raju TS, Capocasale R.
    Int Immunopharmacol; 2007 Jun 01; 7(6):761-72. PubMed ID: 17466910
    [Abstract] [Full Text] [Related]

  • 13. Interaction of human monocyte Fc gamma receptors with rat IgG2b. A new indicator for the Fc gamma RIIa (R-H131) polymorphism.
    Haagen IA, Geerars AJ, Clark MR, van de Winkel JG.
    J Immunol; 1995 Feb 15; 154(4):1852-60. PubMed ID: 7836769
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of allograft rejection by anti-T-cell receptor-alpha beta monoclonal antibodies preserving resistance to bacterial infection.
    Eto M, Yoshikai Y, Nishimura Y, Hiromatsu K, Maeda T, Nomoto K, Kong YY, Kubo RT, Kumazawa J, Nomoto K.
    Immunology; 1994 Feb 15; 81(2):198-204. PubMed ID: 8157269
    [Abstract] [Full Text] [Related]

  • 15. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties.
    Bolt S, Routledge E, Lloyd I, Chatenoud L, Pope H, Gorman SD, Clark M, Waldmann H.
    Eur J Immunol; 1993 Feb 15; 23(2):403-11. PubMed ID: 8436176
    [Abstract] [Full Text] [Related]

  • 16. The effect of aglycosylation on the immunogenicity of a humanized therapeutic CD3 monoclonal antibody.
    Routledge EG, Falconer ME, Pope H, Lloyd IS, Waldmann H.
    Transplantation; 1995 Oct 27; 60(8):847-53. PubMed ID: 7482746
    [Abstract] [Full Text] [Related]

  • 17. In vivo or in vitro anti-CD3 epsilon chain monoclonal antibody therapy for the prevention of lethal murine graft-versus-host disease across the major histocompatibility barrier in mice.
    Blazar BR, Taylor PA, Vallera DA.
    J Immunol; 1994 Apr 01; 152(7):3665-74. PubMed ID: 8144942
    [Abstract] [Full Text] [Related]

  • 18. Construction and characterization of a humanized anti-gamma-Ig receptor type I (Fc gamma RI) monoclonal antibody.
    Graziano RF, Tempest PR, White P, Keler T, Deo Y, Ghebremariam H, Coleman K, Pfefferkorn LC, Fanger MW, Guyre PM.
    J Immunol; 1995 Nov 15; 155(10):4996-5002. PubMed ID: 7594506
    [Abstract] [Full Text] [Related]

  • 19. In vivo immunosuppression induced by a weakly mitogenic antibody to mouse CD3: evidence that induction of long-lasting in vivo unresponsiveness requires TcR signaling.
    Flamand V, Donckier V, Abramowicz D, Goldman M, Vandenabeele P, Urbain J, Moser M, Leo O.
    Cell Immunol; 1994 Aug 15; 157(1):239-48. PubMed ID: 8039247
    [Abstract] [Full Text] [Related]

  • 20. Cytokine release syndrome induced by the 145-2C11 anti-CD3 monoclonal antibody in mice: prevention by high doses of methylprednisolone.
    Alegre ML, Vandenabeele P, Depierreux M, Florquin S, Deschodt-Lanckman M, Flamand V, Moser M, Leo O, Urbain J, Fiers W.
    J Immunol; 1991 Feb 15; 146(4):1184-91. PubMed ID: 1825107
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.